Tonix Pharmaceuticals (NASDAQ:TNXP) Stock Price Down 7.1% – Should You Sell?

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) shares fell 7.1% on Tuesday . The company traded as low as $0.24 and last traded at $0.24. 19,377,092 shares traded hands during trading, a decline of 70% from the average session volume of 64,156,387 shares. The stock had previously closed at $0.26.

Analyst Ratings Changes

Separately, StockNews.com initiated coverage on shares of Tonix Pharmaceuticals in a research note on Thursday, January 9th. They issued a “hold” rating on the stock.

Tonix Pharmaceuticals Stock Down 8.2 %

The firm has a market capitalization of $44.01 million, a price-to-earnings ratio of 0.00 and a beta of 2.02. The business’s 50-day moving average is $0.25 and its two-hundred day moving average is $0.31. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.81 and a current ratio of 3.33.

Tonix Pharmaceuticals (NASDAQ:TNXP) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.23) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.03) by $1.80. The company had revenue of $2.82 million for the quarter, compared to analysts’ expectations of $2.63 million. Tonix Pharmaceuticals had a negative net margin of 1,197.86% and a negative return on equity of 163.95%. On average, equities analysts anticipate that Tonix Pharmaceuticals Holding Corp. will post -17.63 earnings per share for the current year.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.